🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being hailed as a "huge turning point" in the effort against superbug strains of the bacteria, according to health experts.

A Worldwide Challenge

Cases of gonorrhoea are on the rise worldwide, with estimates suggesting more than 82 million infections per year. Particularly high rates are observed in Africa and nations within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. Across England, cases have reached a historical peak, while figures across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an important and timely development in the reality of growing infection rates, escalating drug resistance and the extremely scarce therapeutic options at this time.”

Health officials are particularly alarmed about the surge in antibiotic-resistant strains. The WHO has classified it as a "priority pathogen". Recent surveillance revealed that the effectiveness of key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Drugs Gain Approval

Zoliflodacin, also known as a brand name, was approved by the US FDA in mid-December for use against gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Researchers anticipate that targeted use of this new drug will help delay the development of resistance.

Gepotidacin, created by the drugmaker GSK, also received approval in concurrent days. This drug, which is employed against UTIs, was demonstrated in studies to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin stemmed from a new, not-for-profit approach for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to bring it to fruition.

“This approval marks a significant shift in the therapy of multidrug-resistant gonorrhoea, which until now has been outpacing antibiotic development.”

Testing Results and Worldwide Availability

According to findings published in a prominent scientific publication, the new drug eradicated more than 90% of cases of the STI. This places it at an similar efficacy with the typical regimen, which combines two antibiotics. The study enrolled over 900 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, the non-profit has the rights to license and sell the drug in a wide range of regions with limited resources.

Medical professionals treating patients have shared hope. The availability of a easy-to-administer therapy like this is seen as a "critical tool" for public health efforts. This is considered vital to alleviate the strain of the disease for individuals and to halt the transmission of untreatable gonorrhoea worldwide.